Berk, V. Et Al. 2012. XELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer. HEPATO-GASTROENTEROLOGY , vol.59, no.120 , 2635-2639.

Berk, V., Ozdemir, N., ÖZKAN, M., Aksoy, S., Turan, N., Inal, A., ... Balakan, O.(2012). XELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer. HEPATO-GASTROENTEROLOGY , vol.59, no.120, 2635-2639.

Berk, Veli Et Al. "XELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer," HEPATO-GASTROENTEROLOGY , vol.59, no.120, 2635-2639, 2012

Berk, Veli Et Al. "XELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer." HEPATO-GASTROENTEROLOGY , vol.59, no.120, pp.2635-2639, 2012

Berk, V. Et Al. (2012) . "XELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer." HEPATO-GASTROENTEROLOGY , vol.59, no.120, pp.2635-2639.

@article{article, author={Veli BERK Et Al. }, title={XELOX vs. FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer}, journal={HEPATO-GASTROENTEROLOGY}, year=2012, pages={2635-2639} }